New evidence suggests conducting screening colonoscopies for people in their mid- 50s saves money. But other evidence indicates there may be an upper age limit for the benefits of such screening.
New evidence suggests conducting screening colonoscopies for people in their mid- 50s saves money. But other evidence indicates there may be an upper age limit for the benefits of such screening.
Dr. Jianjun Li and colleagues from Maimonides Medical Center in Brooklyn conducted free screening colonoscopies for 248 consecutive patients with a mean age of 55. Follow-up detected colon cancer and large polyps in about one in 10.The screening program cost $390,000. Had these patients not been screened, their delayed treatment would have cost Medicare nearly $1.3 million. Li released results at the 2008 American College of Gastroenterology meeting.
On the other hand, the U.S. Preventive Services Task Force, an independent panel of the Department of Health and Human Services, recommended that screening cease when men reach age 75, when the possible harm from screening outweighs its benefits. The task force report was published in the Annals of Internal Medicine (2008;149[3]: 185-191).
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.